THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION
AMRYT PHARMA PLC
(“Amryt” or the “Company”)
POSTING OF ANNUAL REPORT AND NOTICE OF AGM
DUBLIN, Ireland, and Boston MA, June 30, 2020, Amryt Pharma (AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that copies of the 2019 Annual Report have been sent to shareholders along with the Notice of Annual General Meeting (“AGM”). Copies are also available from the Company’s website, www.amrytpharma.com.
AGM Arrangements – The Company’s AGM will be held at the Company’s headquarters at 90 Harcourt Street, Dublin 2, Ireland at 12.30 p.m. on Wednesday, 29 July 2020.
The Company continues to closely monitor the evolving situation in respect of COVID-19. The health and welfare of our Shareholders and colleagues is our priority in making arrangements for this year’s AGM. Given the UK and Irish Governments’ ongoing guidance on social distancing and prohibition on non-essential travel and public gatherings relating to the COVID-19 pandemic which will significantly impact the ability of Shareholders to attend the AGM, and in the interests of maintaining the health, safety and welfare of our Shareholders and colleagues, as well as the public in general, this year’s AGM must follow a different format and Shareholders will not, unfortunately, be able to attend the AGM in person.
The AGM will still take place at the time, date and venue stated above but will only be attended by the minimum number of persons legally required to attend in order for the meeting to be quorate. The Directors have decided to hold the AGM at the Company’s headquarters in Dublin, Ireland, to enable Ray Stafford (Non-executive Chairman), Joseph Wiley (Chief Executive Officer) and Rory Nealon (Chief Financial Officer and Company Secretary) to be present and provide for a quorum. Any other Shareholder who attempts to attend in person will currently be refused entry. Therefore, the Board strongly encourages Shareholders to vote on all resolutions being proposed at the AGM by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service, and appointing the Chairman of the AGM as their proxy to cast their votes as directed. We will continue to monitor developments, including the latest UK and Irish Government’s measures relating to COVID-19, and in the event that our AGM arrangements have to change, the Company will issue an announcement via a regulatory information service and on our website at www.amrytpharma/investors/regulatorynews.
AGM – Listen-Live Facility – A listen-live facility will be provided to allow shareholders listen to the business of the meeting. If you wish to listen live to the AGM proceedings, you will be able to do so by dialling the following relevant number at the commencement time of the meeting:
UK: +44 (0) 2071 928338
Ireland: +353 1 506 0650
US: +1 646 741 3167
Shareholders availing of this facility should also ensure to submit their Form of Proxy by the relevant deadline in advance of the AGM, as it will not be possible to vote using the telephone facility.
The Company also encourages Shareholders to submit questions to, or raise matters of concern in relation to the formal business of the AGM with the Board by email to email@example.com, to arrive no later than 12.30 p.m. on 24 July 2020. Please include your full name and contact details. The Company will endeavour to answer any questions during the AGM.
|Amryt Pharma Plc||+353 (1) 518 0200|
|Joe Wiley, CEO
Rory Nealon, CFO/COO
|+44 (0) 20 7408 4090|
|NOMAD and Joint Broker|
|Edward Mansfield, Daniel Bush, John More|
|Stifel||+44 (0) 20 7710 7600|
|Jonathan Senior, Ben Maddison|
|Davy||+353 (1) 679 6363|
|ESM Adviser and Joint Broker|
|John Frain, Daragh O’Reilly|
Consilium Strategic Communications
+44 (0) 20 3709 5700
|Amber Fennell, Matthew Neal, Ashley Tapp|
LifeSci Advisors, LLC
+1 (212) 915 2564
The person making this notification on behalf of Amryt is Rory Nealon, CFO/COO and Company Secretary.
In the United Kingdom this announcement is directed only at (i) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“Order”), (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom this announcement may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being referred to as “relevant persons”). This document must not be acted or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with such persons.
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
Amryt’s commercial business comprises two orphan disease products.
Statements in this announcement with respect to Amryt’s business, strategies, timing for completion of and announcing results from the EASE study, the potential impact of closing enrollment in the EASE study, as well as other statements that are not historical facts are forward-looking statements involving risks and uncertainties which could cause the actual results to differ materially from such statements. Statements containing the words “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project” and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt’s present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt’s ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt’s ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to management.